Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytomegalovirus infection and the influenza vaccination response in older persons
2012-001515-22Phase 4Completed
- Sponsor
- KU Leuven
- Start
- Mar 2012
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4 trial of ARCT-2138 in influenza (2 arms), sponsored by KU Leuven. Primary endpoints: Influenza humoral immune response after vaccination, Influenza cell-mediated immune response after vaccination and 1 more. Started Mar 2012; status: completed.
02
Drugs
ARCT-2138
03
Conditions
influenza
Beyond the preview
Go deeper on 2012-001515-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001515-22.